Nextstellis®: A new drug update 

  A new combined oral contraceptive was approved by the FDA (Nextstellis®) in April 2021.1 Nextstellis contains estetrol, an estrogen that can be manufactured from plants and that was originally derived naturally during pregnancy from the fetus liver, and drospirenone, a progestin found in other currently available contraceptives. Drospirenone has antiandrogenic and anti-mineralocorticoid activity.2 Estetrol differs…

Read More

A Primer on Reproductive Justice for Pharmacy Professionals

A pharmacy student reflects on what she learned from “Sex & Gender 101” — a gender-inclusive series designed to show learners how to take the first steps to providing care that addresses the specific needs of LGBTQI+ patients. This series includes a glossary of terms, resources for further study, and a “cheat sheet” for providers interacting with patients across the gender spectrum.

Read More

Sex & Gender 101

A pharmacy student reflects on what she learned from “Sex & Gender 101” — a gender-inclusive series designed to show learners how to take the first steps to providing care that addresses the specific needs of LGBTQI+ patients. This series includes a glossary of terms, resources for further study, and a “cheat sheet” for providers interacting with patients across the gender spectrum.

Read More

Putting Policy into Practice: Contraception Care in San Francisco Pharmacies

What makes some pharmacies more successful than others at implementing pharmacist-prescribed contraception care? To answer this question, we conducted a study to determine the extent of hormonal contraceptive prescribing, also referred to as furnishing in California, among San Francisco community pharmacies, and identify the factors that led to successful implementation.

Read More